Allogene Therapeutics Inc Cash Flow-to-Debt Ratio
Allogene Therapeutics Inc cash flow-to-debt ratio. Allogene Therapeutics Inc (ALLO) has a Cash Flow-to-Debt Ratio of -0.24x as of September 2025, meaning its operating cash flow of $-29.69 Million could theoretically repay 0% of its total liabilities ($124.44 Million) in one year. See financial flexibility index of Allogene Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Allogene Therapeutics Inc (2017–2024)
Cash flow-to-debt ratio of Allogene Therapeutics Inc from 2017 to 2024. Historical debt coverage capacity for Allogene Therapeutics Inc across 8 annual periods. Check Allogene Therapeutics Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Allogene Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2017–2024)
Allogene Therapeutics Inc cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Allogene Therapeutics Inc. For the full cash flow conversion analysis, see ALLO cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.58x | $-200.30 Million | $126.53 Million | ▲ +13.0% |
| 2023 | -1.82x | $-237.73 Million | $130.60 Million | ▼ -27.7% |
| 2022 | -1.43x | $-220.52 Million | $154.70 Million | ▲ +3.1% |
| 2021 | -1.47x | $-184.81 Million | $125.63 Million | ▼ -89.4% |
| 2020 | -0.78x | $-115.09 Million | $148.21 Million | ▲ +49.8% |
| 2019 | -1.55x | $-137.35 Million | $88.78 Million | ▼ -144.9% |
| 2018 | -0.63x | $-44.65 Million | $70.69 Million | ▲ +100.0% |
| 2017 | -22326.50x | $-44.65 Million | $2.00K | — |